Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cyclosporin A--dermatologic indications].

G Mahrle1, H J Schulze

  • 1Universitäts-Hautklinik Köln.

Zeitschrift Fur Hautkrankheiten
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression-, aggression-, survival and outcome characteristics in Merkel cell carcinomas in 176 patients.

Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery·2025
Same author

Immune checkpoint analysis in ear cancer.

Head & face medicine·2023
Same author

Basal cell carcinoma risk and solar UV exposure in occupationally relevant anatomic sites: do histological subtype, tumor localization and Fitzpatrick phototype play a role? A population-based case-control study.

Journal of occupational medicine and toxicology (London, England)·2020
Same author

A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy.

The British journal of dermatology·2018
Same author

Prospective multicentre cohort study on 9154 surgical procedures to assess the risk of postoperative bleeding - a DESSI study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016
Same author

[In honor of Professor Dr. Dr. h.c. G. K. Steigleder on the occasion of his 90th birthday].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2015

Low-dose systemic cyclosporin A (CSA) effectively treated psoriasis with no side effects. Topical CSA showed subclinical effects, penetrating skin without systemic absorption, reducing neutrophils in psoriatic lesions.

Area of Science:

  • Immunopharmacology
  • Dermatology

Background:

  • Cyclosporin A (CSA) is an immunosuppressive drug with potential applications in dermatological conditions.
  • Understanding CSA's pharmacology and clinical efficacy for psoriasis is crucial.

Purpose of the Study:

  • To review the pharmacology and clinical indications of cyclosporin A (CSA).
  • To evaluate the efficacy and safety of systemic and topical CSA in treating psoriasis.

Main Methods:

  • Systemic CSA administered at 2.5 mg/kg/d for 10 weeks to 13 psoriasis patients.
  • Topical CSA (1%, 5%, 10% gel/ointment) applied to 40 psoriasis patients.
  • Quantification of CSA in skin and blood using polyclonal RIA.
  • Assessment of Psoriasis Area and Severity Index (PASI) score reduction.

Related Experiment Videos

  • Evaluation of neutrophil counts and epidermal DNA synthesis in psoriatic skin.

    • Main Results:

    • Systemic CSA (2.5 mg/kg/d) achieved a 75% PASI score reduction in 13 patients with no adverse reactions.
    • Topical CSA demonstrated subclinical effects, penetrating deep skin layers and accumulating significantly (up to 3,880 ng/g).
    • Topical CSA did not result in measurable blood concentrations, indicating no systemic absorption.
    • Topical CSA selectively and significantly reduced neutrophils in psoriatic skin but did not impact epidermal DNA synthesis.

    Conclusions:

    • Low-dose systemic CSA is a safe and effective treatment for chronic stationary psoriasis.
    • Topical CSA penetrates psoriatic skin effectively without systemic absorption, showing localized biological effects.
    • CSA's mechanism in psoriasis may involve selective neutrophil modulation rather than direct effects on epidermal DNA synthesis.